Trial design in NASH—realities and challenges (original) (raw)

Clinical trials

Nature Reviews Gastroenterology & Hepatology volume 8, pages 424–425 (2011)Cite this article

Subjects

The conclusions of clinical trials in patients with nonalcoholic steatohepatitis (NASH) can be influenced by the study design. A group of experts has published recommendations for the design of studies in NASH; these recommendations represent a step towards a standardized methodology for clinical trials in this setting.

This is a preview of subscription content, access via your institution

Access options

Subscribe to this journal

Receive 12 print issues and online access

$189.00 per year

only $15.75 per issue

Buy this article

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

References

  1. Sanyal, A. J. et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology 54, 344–353 (2011).
    Article PubMed Google Scholar
  2. Musso, G., Gambino, R., Cassader, M. & Pagano, G. Meta-analysis: Natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann. Med. doi:10.3109/07853890.2010.518623.
    Article PubMed Google Scholar
  3. Dam-Larse, S. et al. Final results of a long-term, clinical follow-up in fatty liver patients. Scand. J. Gastroenterol. 44, 1236–1243 (2009).
    Article Google Scholar
  4. Ekstedt, M. et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 44, 865–873 (2006).
    Article CAS PubMed Google Scholar
  5. Younossi, Z. et al. Pathologic criteria for non-alcoholic steatohepatitis (NASH): Inter-protocol agreement and ability to predict liver-related mortality. Hepatology 53, 1874–1882 (2011).
    Article PubMed Google Scholar
  6. Angulo, P. Diagnosing steatohepatitis and predicting liver-related mortality in patients with NAFLD: Two distinct concepts. Hepatology 53, 1792–1794 (2011).
    Article PubMed Google Scholar
  7. Sanyal, A. J. et al. NASH CRN. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N. Engl. J. Med. 362, 1675–1685 (2010).
    Article CAS PubMed PubMed Central Google Scholar
  8. Nobili, V. et al. Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial. Hepatology 48, 119–128 (2008).
    Article CAS PubMed Google Scholar
  9. Lavine, J. E. et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA 305, 1659–1668 (2011).
    Article CAS PubMed PubMed Central Google Scholar
  10. Sanyal, A. J. ACP Journal Club: vitamin E, but not pioglitazone, improved nonalcoholic steatohepatitis in nondiabetic patients. Ann. Intern. Med. 153, JC3–JC12 (2010).
    CAS PubMed Google Scholar

Download references

Acknowledgements

This article was supported in part by R01 grant DK82426 from the NIH to P. Angulo.

Author information

Authors and Affiliations

  1. Division of Digestive Diseases & Nutrition, Department of Medicine, University of Kentucky Medical Center, 800 Rose Street, Room MN649, Lexington, 40536-0298, KY, USA
    Paul Angulo

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

About this article

Cite this article

Angulo, P. Trial design in NASH—realities and challenges.Nat Rev Gastroenterol Hepatol 8, 424–425 (2011). https://doi.org/10.1038/nrgastro.2011.125

Download citation